Grail Stock

Blood-sampling device

Sign up today and learn more about Grail Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.



Notable Investors

Sequoia Capital China


Menlo Park CA, US

Total Funding


About Grail Stock

Grail develops a pan-cancer screening test designed to detect cancer early. Its pan-cancer screening test measures circulating nucleic acids in blood using high-intensity sequencing, population-scale clinical trials, enabling doctors to develop blood tests for early-stage cancer detection.


Funding History

January 2016$85.0M
November 2017$1.2B
May 2018$300M
November 2019$392M


Chief Executive Officer

Hans Bishop

Chief Operating Officer & Chief Financial Officer

Matthew Young

Chief Scientific Officer

Alex Aravanis


EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 300K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: